IN RESPONSE:
To the Editor:
In response to the Letter to the Editor, we will substantiate pointby-point why our study is appropriate and supportive of the favorable efficacy and tolerability profile of tapentadol prolonged release (TAP). Our study was designed to test the hypotheses of noninferiority (followed by superiority) for TAP vs. oxycodone/naloxone PR (OXN) in a preplanned, 2-step statistical testing procedure for two co-primary endpoints. 1, 2 The study hypotheses assumed an efficacy of OXN comparable to that of oxycodone CR (OXY) 3 and a difference in tolerability of OXN vs. OXY related to naloxone's (nonsystemic) effect on opioid-induced constipation. As per relevant EMA guideline, 4 the criteria for switching between noninferiority and superiority were met (lower boundary of the 97.5% RCI of the difference not including zero). As a result, the trial provided confirmatory evidence of superiority of TAP vs. OXN.
1. Open-label vs. double-blind study design: Efficacy and safety of TAP vs. OXY has already been established in three large double-blind RCTs in osteoarthritis and low back pain. 5, 6 A preplanned, pooled analysis of these trials showed superiority of TAP over OXY for the primary efficacy endpoints, validated quality-of-life parameters, and gastrointestinal tolerability. 7 With this level of evidence already established, it is appropriate to collect more "real-world" data. Evidence derived from such "real-world"/"pragmatic" 7 The pickup arm was intended to provide patients with a fair chance to achieve pain relief with acceptable tolerability, a setting that can be considered a reflection of clinical practice; in contrast, a switch from TAP to OXN was (evidence-based) unlikely to provide additional benefits. Would this approach have introduced relevant bias? The discontinuation rate with OXN in the present study (62.5%) was comparable to that with OXY (61.7%) in large-scale, double-blind, phase III RCTs which did not include pickup arms. 7 This indicates that the pickup arm did not significantly influence discontinuation rates. 3. Dynamics of titration: Referring to both prescribing information (PI) as the relevant guidelines for treatment initiation and maintenance, the titration regimen used can be considered fair and adequate in the context of the trial setting and objectives. It allowed for dose increases at an equianalgesic ratio, thereby avoiding bias due to underdosing of one compound in cases of unequal dose steps. According to international prescribing information, OXN may be titrated in steps of 10/5 mg bid as done in our trial and potentially faster (every 1-2 days 9, 10 ). But it is unlikely that prolonging the titration steps by 1 day causes any relevant bias. Furthermore, it addresses the needs of a sensitive, non-opioid-pretreated population, which is highly susceptible to opioid side effects such as nausea and vomiting. If the slower titration (every 3 days) led to bias, this could only have been due to lack of efficacy. During the titration phase, only 16.6% of dropouts in the TAP arm and 18.8% in the OXN arm were due to lack of efficacy, which strongly argues against a bias due to prolongation of the titration interval by 1 day.
4.
Response criterion for the titration phase: There were 2 alternative criteria to enter the continuation phase of the study:
The first required a pain intensity ≤ 4 (on the well-established NRS-3) with acceptable tolerability at the end of titration; the second was meant to offer a fair chance to patients to continue treatment if pain was reduced to ≤ 5 at the highest tolerated dose and continuation was justifiable. The quantitative pain reduction achieved up to that point in the full analysis set, as requested by the authors of the letter, is published in our article (figure 5) 1 with À3.4 and À2.5 for TAP and OXN, respectively.
Inclusion criteria:
This study was intended to evaluate treatment responses in patients with pain with a neuropathic component. 1 As opioid monotherapy is often insufficient for the treatment of neuropathic pain, co-analgesics are frequently added. Excluding patients taking co-analgesics could have led to selection of patients with mild neuropathic symptoms. Pain (NRS) and PainDETECT scores in these patients were allowed to be slightly lower at enrollment due to the use of co-analgesics, expecting that scores would rise after their mandatory washout and they had to be ≥ 6 (for NRS) and "unclear" (PainDETECT) at randomization (baseline) for all patients. 6. Imputation: The use of any type of imputation or no imputation represents a form of bias. As per the EMA guidance for missing data, there is no universally applicable method of handling missing data. 11 The imputation method was fully prespecified at the beginning of the trial. The choice of using LOCF is based on the fact that this method was widely used for assessing the efficacy in pain, it provides a pragmatic and reasonable conservative imputation method, and it is used in previous TAP trials, thus allowing comparability of the trial results.
We maintain that this trial taken together with other data available on TAP supports its favorable efficacy and tolerability profile. 
